Title
Author
DOI
Article Type
Special Issue
Volume
Issue
METASTATIC DIRECTED THERAPY IN OLIGOMETASTATIC PROSTATE CANCER
1Division of Urology, University of Cincinnati College of Medicine. Cincinnati, OH
*Corresponding Author(s): Connor G. Hoge E-mail: hogecg@mail.uc.edu
Connor G. Hoge ,Abhinav Sidana. METASTATIC DIRECTED THERAPY IN OLIGOMETASTATIC PROSTATE CANCER. Journal of Men's Health. 2018. 14(3);1-2.
1. Ost P, Reyenders D, Decaestecker K, et al. Surveil-lance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol 2017. J Clin Oncol. 2018 Feb 10;36(5):446-453. doi: 10.1200/JCO.2017.75.4853. Epub 2017 Dec 14.
2. Heidenreich A, Bastian PJ, Bellmunt J, et al. EAU guide-lines on prostate cancer part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014:65(2):467–79.
3. Taylor LG, Canfield SE, DU XL: Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 2009;115(11):2388–99.
4. Schweizer MT, Zhou XC, Wang H, et al. Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred an-drogen deprivation therapy. Ann Oncol 2013;24:2881-6.
5. Ost P, Bossi A, Decaestecker K et al. Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 2015;67:852–63.
6. Phillips RM, Hayman J, Tran PT. Stomping out hormone-sensitive metastases with local therapies in prostate cancer. J Clin Oncol. 2018 Feb 10;36(5):435–37. doi: 10.1200/JCO.2017.76.5495. Epub 2017 Dec 14.
7. Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF. Role of radical prostatectomy in metastatic prostate cancer: A review. Urol Oncol 2017 Apr;35(4):125–34. Epub 2017 Feb 9.
Top